作者: Evan T. Keller
DOI: 10.1007/978-1-59745-224-3_11
关键词: Prostate cancer 、 Cancer 、 Parathyroid hormone-related protein 、 Bone resorption 、 Oncology 、 RANKL 、 Biology 、 Internal medicine 、 Metastasis 、 Bone metastasis 、 Osteoprotegerin
摘要: Prostate cancer (CaP) is the most frequently diagnosed in men and second leading cause of death among United States (1). The common site CaP metastasis bone with skeletal metastases identified at autopsy up to 90% patients dying from CaP. Understanding how tumor interacts may lead toward identifying therapies prevent or diminish consequences metastases. forms a mixture osteolytic (excess resorption) osteoblastic production) component caused, part, through cancer-mediated activation receptor nuclear factor-κ B ligand (RANKL) pathway. Blocking RANKL has been shown successfully inhibit establishment progression animal models. Other factors that are important development CaP-induced lesions include interleukin (IL)-6, parathyroid hormonerelated protein (PTHrP), matrix metalloproteinases (MMPs). mechanism which induces less clear; however, produces variety promote an overall phenotype, including inhibitor RANKL, osteoprotegerin (OPG); vascular-active agent, endothelin (ET)-1; transforming growth factor (TGF)-β. Several methods target being explored clinics, bisphosphonates, inhibitors ET-1. To effectively treat metastases, targeting both components simultaneously be important.